Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by icecubeon Sep 29, 2015 10:02am

37 Views

Post# 24144489

RE:RE:RE:RE:RE:RE:RE:RE:Catching a Knife?

As noted previously, there are many other factors, seasonality being but one, for going long now.

Styless wrote:
icecube wrote: Brave or foolish, we'll see. I have to wonder if we've seen the finish of 'end of quarter' selling/repositioning of portfolios. Also, seasonally, October, November and December tend to be 'up' months.

Craigbad wrote: Your brave to be buying. I see this getting hammered in tax loss selling in the coming months. If anything i would think smart longs would be selling now and buying in december when the price should be signifigantly lower if you like the long term potential.

If you believed in your seasonality, why wouldn't you pick a better name to play for a macro seasonal move? You picked the worse performing company that has negative catalysts that will counteract any seasonality. You actually picked the worse name for your thesis.ha

If anything, you're going to see massive tax loss selling in this loser that's down 71% this year alone.